|
1
|
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
|
J Clin Oncol
|
2005
|
2.52
|
|
2
|
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
|
Eur J Cancer
|
2013
|
1.11
|
|
3
|
Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
|
Clin Cancer Res
|
2012
|
1.06
|
|
4
|
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
|
Eur J Cancer
|
2012
|
0.96
|
|
5
|
Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group.
|
J Clin Oncol
|
2007
|
0.93
|
|
6
|
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
|
Eur J Cancer
|
2013
|
0.90
|
|
7
|
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
|
Clin Cancer Res
|
2005
|
0.88
|
|
8
|
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
|
J Clin Oncol
|
2005
|
0.88
|
|
9
|
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
|
Cancer Chemother Pharmacol
|
2004
|
0.84
|
|
10
|
A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
|
Eur J Cancer
|
2008
|
0.82
|
|
11
|
Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
|
Oncology
|
2015
|
0.75
|